Literature DB >> 10946038

Pulmonary vascular disease in Down's syndrome with complete atrioventricular septal defect.

K Suzuki1, S Yamaki, S Mimori, Y Murakami, K Mori, Y Takahashi, T Kikuchi.   

Abstract

We sought to determine the predisposing factors of pulmonary vascular disease (PVD) in complete atrioventricular septal defect. Down's syndrome is considered a risk factor for PVD, but the progression of PVD differs in each case. Morphometric analysis in autopsied hearts showed that Rastelli type A morphology had a narrower left ventricular outlet and a wider right ventricular outlet than did type C. In 81 consecutive patients with Down's syndrome who underwent cardiac catheterization, we estimated the following variables: Rastelli subtypes, pulmonary vascular resistance, pulmonary-to-systemic flow ratio, patients' age, and operative outcome. The hemodynamic variables in those <1 year old did not differ between the groups with type A and type C. However, all 5 patients with fatal pulmonary hypertension in early infancy had type A morphology. The lung histology revealed that 3 of these patients already had irreversible PVD. At >/=1 year old, those with type A showed a significantly higher pulmonary vascular resistance (p <0.001) and a lower pulmonary to systemic flow ratio (p <0.05) than did those <1 year old. In contrast, neither of these variables in the type C group differed between those >/=1 and <1 year old. Moreover, those with type A had a greater risk of being contraindicated for surgical repair (p <0.05). We suspect, therefore, that type A morphology is an independent risk factor for PVD in those with Down's syndrome associated with this anomaly. This hemodynamic influence could become obvious once patients are >/=1 year old. It may also sometimes result in irreversible PVD even in early infancy.

Entities:  

Mesh:

Year:  2000        PMID: 10946038     DOI: 10.1016/s0002-9149(00)00960-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine.

Authors:  Clifford L Cua; Lynette K Rogers; Louis G Chicoine; Molly Augustine; Yi Jin; Patricia L Nash; Leif D Nelin
Journal:  Eur J Pediatr       Date:  2010-12-01       Impact factor: 3.183

2.  Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates.

Authors:  C L Cua; A Blankenship; A L North; J Hayes; L D Nelin
Journal:  Pediatr Cardiol       Date:  2007-05-05       Impact factor: 1.655

3.  A study to determine the prevalence of pulmonary arterial hypertension in children with Down syndrome and congenital heart disease.

Authors:  Mukti Sharma; Sanjeev Khera; Vishal Sondhi; Amit Devgan
Journal:  Med J Armed Forces India       Date:  2013-02-23

4.  Repair of complete atrioventricular septal defect in infants with down syndrome: outcomes and long-term results.

Authors:  Margarita R Tumanyan; Olga V Filaretova; Vera V Chechneva; Ruben S Gulasaryan; Iuliia V Butrim; Leo A Bockeria
Journal:  Pediatr Cardiol       Date:  2014-08-07       Impact factor: 1.655

Review 5.  Cytogenomic Aberrations in Congenital Cardiovascular Malformations.

Authors:  Mahshid Azamian; Seema R Lalani
Journal:  Mol Syndromol       Date:  2016-04-26

6.  A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI Pediatric Taskforce, Panama 2011.

Authors:  Maria Jesus Del Cerro; Steven Abman; Gabriel Diaz; Alexandra Heath Freudenthal; Franz Freudenthal; S Harikrishnan; Sheila G Haworth; Dunbar Ivy; Antonio A Lopes; J Usha Raj; Julio Sandoval; Kurt Stenmark; Ian Adatia
Journal:  Pulm Circ       Date:  2011       Impact factor: 3.017

7.  Prevalence of Congenital Heart Disease and Pulmonary Hypertension in Down's Syndrome: An Echocardiographic Study.

Authors:  Nilda Espinola-Zavaleta; María Elena Soto; Angel Romero-Gonzalez; Lidia Del Carmen Gómez-Puente; Luis Muñoz-Castellanos; Aasha S Gopal; Candace Keirns; Eulo Lupi-Herrera
Journal:  J Cardiovasc Ultrasound       Date:  2015-06-26

8.  Effect of bosentan on exercise capacity and clinical worsening in patients with dual down and eisenmenger syndrome.

Authors:  Giorgio Serino; Marco Guazzi; Angelo Micheletti; Carlo Lombardi; Rossella Danesi; Diana Negura; Mario Carminati; Massimo Chessa
Journal:  Clin Med Insights Cardiol       Date:  2013-02-06

9.  Long-term results of treatment with bosentan in adult Eisenmenger's syndrome patients with Down's syndrome related to congenital heart disease.

Authors:  Roberto Crepaz; Cristina Romeo; Donato Montanaro; Stefano De Santis
Journal:  BMC Cardiovasc Disord       Date:  2013-09-18       Impact factor: 2.298

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.